碘[I-125](Iodine[I-125]) - _专利_临床

概要

基本信息

药物类型

小分子化药、治疗用放射药物

别名-

靶点-

作用方式-

作用机制

电离辐射发射源

治疗领域-

在研适应症-

非在研适应症-

原研机构-

在研机构-

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式I

InChIKeyZCYVEMRRCGMTRW-YPZZEJLDSA-N

CAS号14158-31-7

关联

9

项与碘[I-125] 相关的临床试验

NCT06367010

/ CompletedN/AIIT

Clinical Efficacy and Safety Analysis of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients

A retrospective analysis was conducted on patients with radioiodine-refractory thyroid carcinoma (RRTC) who underwent radioactive 125I seed implantation combined with anlotinib from January 2019 to October 2024 at Jiangxi Cancer Hospital. Data on tumor size changes before and after treatment, serological tests (including serum TG, TgAb, CTn, CEA, etc.), changes in patients' pain scores, and side effects were collected to evaluate the clinical efficacy and safety of this therapy.

开始日期2019-01-01

申办/合作机构

江西省肿瘤医院（江西省第二人民医院、江西省癌症中心）

NL-OMON37110

/ Completed临床2期IIT

Prospective multi-centre study of low-dose Iodine125 (I-125) prostate brachytherapy performed after transurethral resection. PROBATE study - I125 postTURP

开始日期2013-08-08

申办/合作机构-

JPRN-jRCT1051180150

/ CompletedN/A

Clinical efficay focusing on I-125 salvage permanent brachytherapy in men diagnosed prostate cancer who recurred after external beam therapy

开始日期2012-08-22

申办/合作机构-

100 项与碘[I-125] 相关的临床结果

登录后查看更多信息

100 项与碘[I-125] 相关的转化医学

登录后查看更多信息

100 项与碘[I-125] 相关的专利（医药）

登录后查看更多信息

5,233

项与碘[I-125] 相关的文献（医药）

2025-05-01·Marine Pollution Bulletin

Spatial-temporal variations of kelp 129I contents in coastal waters of China before and after the Fukushima Daiichi Nuclear Power Plant accident

Article

作者: Ge, Baozhu ; Yang, Xiaoqi ; Liu, Jialin ; Zhang, Luyuan ; Zhuang, Shuhan ; Sun, Xiaole ; Xie, Guozhi ; Liu, Xiaowen ; Sun, Weidong ; Zhao, Chang ; Qiao, Fangli ; Fan, Yukun ; Fang, Sheng ; Liu, Qi ; Duan, Delin

Radioactive ¹²⁹I isotope, as one of the main products of the nuclear fission process, can be applied to track radioactive substances in the environment. So far, limited studies have investigated the spatial-temporal distribution of ¹²⁹I in marine ecosystems including the ¹²⁹I isotope released via nuclear activities. This study reports the ¹²⁹I concentrations of kelps collected from the shallow coastal Yellow Sea and East China Sea from 2009 to 2021. The results show that the kelp ¹²⁹I concentrations increased by 5 times in our studied areas in 2011 right after the Fukushima Daiichi Nuclear Power Plant (FDNPP) accident and then decreased back to the pre-accident level in the following years. Meanwhile, the kelp ¹²⁹I concentrations in the Yellow Sea decreased much faster than those in the East China Sea between 2012 and 2021, which could be attributed to large river inputs that sustain a high supply of ¹²⁹I to coastal areas. Our observations suggest that the FDNPP accident may not be the cause of the increase in ¹²⁹I in coastal kelps in 2011. Instead, the ¹²⁹I emitted by nuclear fuel reprocessing plants (NFRPs) and being flushed into coastal areas by rivers could be main source of ¹²⁹I to coastal kelps.

2025-04-02·ACS Chemical Neuroscience

Comparative Radiotracing Quantifies Brain Cellular Uptake and Catabolism of Bispecific Antibodies Targeting Transferrin Receptor and CD98hc

Article

作者: Bond, Layne G. ; Tessier, Peter M. ; Tripu, Deepika R. ; Veire, Jacob L. ; Greineder, Colin F. ; Lucas, Michael J.

Bispecific antibodies (bAbs) that engage cerebrovascular targets, induce transport across the blood-brain barrier (BBB), and redistribute to secondary targets within the brain parenchyma have the potential to transform the diagnosis and treatment of a wide range of central nervous system disorders. Full understanding of the pharmacokinetics (PK) of these agents, including their potential for delivering cargo into brain parenchymal cells, is a key priority for the development of numerous potential therapeutic applications. To date, the brain PK of bAbs that target transferrin receptor (TfR-1) and CD98 heavy chain (CD98hc) has been characterized using techniques incapable of distinguishing between CNS clearance of intact protein from uptake and catabolism by brain parenchymal cells. Herein, we address this knowledge gap via a comparative radiotracing strategy using two radioisotopes with distinct residualizing properties, iodine-125 (I-125) and zirconium-89 (Zr-89). We first identify reaction conditions for tetravalent chelator modification and Zr-89 radiolabeling that do not adversely affect in vitro or in vivo function. We then use comparative radiotracing to define the PK of TfR-1 and CD98hc targeted bAbs without a parenchymal target, generating quantitative evidence of TfR-1-mediated cellular uptake and catabolism that implicates these processes in previously reported differences in the brain retention of IgGs shuttled across the BBB via these two pathways. Finally, we perform comparative radiotracing on a TfR-1 bAb with an internalizing neuronal target (TrkB), demonstrating rapid divergence of Zr-89 and I-125 PK curves, with a > 30-fold difference in brain content of the two radioisotopes. Together, these results establish comparative radiotracing as a valuable technique for identifying internalizing cellular targets within the brain parenchyma and quantifying the extent and timing of bAb uptake and catabolism following target engagement.

2025-03-01·International Journal of Oral and Maxillofacial Surgery

Multimodal image-guided surgical robot versus 3D-printed template for brachytherapy of malignant tumours in the skull base and deep facial region: a clinical comparative study

Article

作者: Lin, Q ; Zhang, H ; Jin, N ; Xing, L ; Meng, F ; Zhu, L

This study compared a multimodal image-guided robot and three-dimensionally (3D) printed templates for implanting iodine-125 (I¹²⁵) radioactive seeds in patients with malignant tumours in the skull base and deep facial region. Seventeen patients who underwent I¹²⁵ radioactive seed implantation between December 2018 and December 2019 were included. The operation time, intraoperative blood loss, and accuracy of seed implantation were compared between the multimodal image-guided robot-assisted implantation (experimental) group (n = 7) and 3D-printed template-assisted implantation (control) group (n = 10). In total, 291 seeds were implanted in the experimental group and 436 in the control group; the mean error of seed implantation accuracy was 1.95 ± 0.13 mm and 1.90 ± 0.08 mm, respectively (P = 0.309). The preparation time was 26.13 ± 5.28 min in the experimental group and 0 min in the control group, while the average operation time was 34.44 ± 6.39 min versus 43.70 ± 6.06 min, respectively. The intraoperative blood loss was 4.96 ± 1.76 ml (experimental) versus 8.97 ± 2.99 ml (control) (P = 0.123). Multimodal image-guided robot-assisted I¹²⁵ radioactive seed implantation met the clinical requirements for treating malignant tumours in the skull base and deep facial regions.

100 项与碘[I-125] 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	碘[I-125]	V09GB	DB14804

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO_GU2014	N/A	-	300	Pd-103	築鬱膚顧淵製願壓遞糧(淵艱襯積齋願遞網窪觸) = 選鹹鏇夢願觸積蓋遞淵鹽壓衊壓積選構鹽築選 (獵衊簾齋鏇遞夢構觸鹽 ) 更多	-	2014-02-01
ASCO_GU2014	N/A	-	300	I-125	築鬱膚顧淵製願壓遞糧(淵艱襯積齋願遞網窪觸) = 獵製夢淵觸廠夢衊鏇簾鹽壓衊壓積選構鹽築選 (獵衊簾齋鏇遞夢構觸鹽 ) 更多	-	2014-02-01
I-125 Treated Prostate Cancer Patients (ASTRO2012)	N/A	前列腺癌	-	I-125 (Preplanned implant using preloaded needles)	窪鑰蓋製餘壓鏇憲壓範(艱觸廠餘廠鏇夢壓齋鑰) = 醖簾衊蓋壓壓鏇齋憲積襯範獵觸膚鑰遞壓窪衊 (網遞鬱壓鑰鏇觸積糧壓 )	积极	2012-11-01
I-125 Treated Prostate Cancer Patients (ASTRO2012)	N/A	前列腺癌	-	I-125 (Intraoperative treatment planning)	窪鑰蓋製餘壓鏇憲壓範(艱觸廠餘廠鏇夢壓齋鑰) = 餘積遞鏇鹽製觸膚衊糧襯範獵觸膚鑰遞壓窪衊 (網遞鬱壓鑰鏇觸積糧壓 )	积极	2012-11-01
1124 (AUA2012)	N/A	局限性前列腺癌	267	I-125 (Patients with seed migration)	廠艱醖觸遞積膚鬱艱淵(鑰廠窪窪顧襯選窪鹽膚) = not significantly different 壓壓膚糧夢製繭蓋襯衊 (夢衊膚簾齋鬱膚壓窪醖 )	-	2012-04-01
2041 (AUA2010)	N/A	Gleason score \| PSA	560	Low-dose-rate Iodine-125 brachytherapy	(鹹餘夢願遞鹹膚餘壓製) = 窪蓋選製壓觸選觸窪築夢廠鹽餘範鏇蓋遞醖鬱 (鹹憲壓網憲網膚襯簾選, 75% ~ 81%) 更多	-	2010-04-01